236 related articles for article (PubMed ID: 33338869)
1. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
2. Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC).
Řezníčková E; Krajčovičová S; Peřina M; Kovalová M; Soural M; Kryštof V
Eur J Med Chem; 2022 Dec; 243():114792. PubMed ID: 36191408
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
[TBL] [Abstract][Full Text] [Related]
4. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation.
Tokarski RJ; Sharpe CM; Huntsman AC; Mize BK; Ayinde OR; Stahl EH; Lerma JR; Reed A; Carmichael B; Muthusamy N; Byrd JC; Fuchs JR
Eur J Med Chem; 2023 Jun; 254():115342. PubMed ID: 37071962
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.
Wu T; Zhang Z; Gong G; Du Z; Xu Y; Yu S; Ma F; Zhang X; Wang Y; Chen H; Wu S; Xu X; Qiu Z; Li Z; Wu H; Bian J; Wang J
Eur J Med Chem; 2023 Nov; 260():115774. PubMed ID: 37672930
[TBL] [Abstract][Full Text] [Related]
7. CDK9 inhibitors in acute myeloid leukemia.
Boffo S; Damato A; Alfano L; Giordano A
J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
[TBL] [Abstract][Full Text] [Related]
8. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
[TBL] [Abstract][Full Text] [Related]
10. Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia.
Wu T; Yu B; Gong W; Zhang J; Yu S; Tian Y; Zhao T; Li Z; Wang J; Bian J
Eur J Med Chem; 2023 Nov; 259():115711. PubMed ID: 37572539
[TBL] [Abstract][Full Text] [Related]
11. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
[TBL] [Abstract][Full Text] [Related]
12. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
[TBL] [Abstract][Full Text] [Related]
13. Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy.
Mallareddy JR; Singh S; Boghean L; Natarajan A
Future Med Chem; 2022 Jan; 14(3):131-134. PubMed ID: 34814708
[No Abstract] [Full Text] [Related]
14. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
16. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
17. Development of selective mono or dual PROTAC degrader probe of CDK isoforms.
Zhou F; Chen L; Cao C; Yu J; Luo X; Zhou P; Zhao L; Du W; Cheng J; Xie Y; Chen Y
Eur J Med Chem; 2020 Feb; 187():111952. PubMed ID: 31846828
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.
Li J; Liu T; Song Y; Wang M; Liu L; Zhu H; Li Q; Lin J; Jiang H; Chen K; Zhao K; Wang M; Zhou H; Lin H; Luo C
J Med Chem; 2022 Aug; 65(16):11034-11057. PubMed ID: 35925880
[TBL] [Abstract][Full Text] [Related]
19. Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion.
Burslem GM; Song J; Chen X; Hines J; Crews CM
J Am Chem Soc; 2018 Dec; 140(48):16428-16432. PubMed ID: 30427680
[TBL] [Abstract][Full Text] [Related]
20. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]